Molecular Regulation of Folate and Antifolate Transport

叶酸和抗叶酸转运的分子调节

基本信息

  • 批准号:
    10652998
  • 负责人:
  • 金额:
    $ 29.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1993
  • 资助国家:
    美国
  • 起止时间:
    1993-02-12 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT Folates are anionic molecules that cross biological membranes poorly by diffusion. Folate uptake is principally mediated by the reduced folate carrier (RFC; SLC19A1) and the proton-coupled folate transporter (PCFT; SLC46A1). Upon internalization, folates facilitate one-carbon (C1) metabolism, leading to synthesis of glycine, serine and methionine, and purine nucleotides and thymidylate. C1 metabolism encompasses cytosolic and mitochondrial pathways connected by an interchange between serine, glycine and formate. The ubiquitously expressed RFC is the major membrane transporter for folates in cells and tissues. RFC is also an important transporter of clinically used C1 inhibitors (e.g., pemetrexed) for cancer, as well as other indications, and loss of RFC is associated with drug resistance. PCFT mediates folate absorption in the upper gastrointestinal tract. PCFT levels in other tissues are generally modest. Unlike RFC, PCFT transport is optimal at acidic pH, approximating the tumor microenvironment. PCFT is widely expressed in human tumor cell lines and primary specimens. We discovered novel cytotoxic PCFT-targeted C1 inhibitors for cancer and established a comprehensive structure-activity relationship for PCFT that is distinct from RFC. Novel pyrrolopyrimidine compounds (AGF94 & AGF347) showed potent anti-proliferative activities toward PCFT-expressing tumors that were augmented at acid pH. Following internalization, AGF94 inhibited de novo purine (DNP) biosyn- thesis at β-glycinamide ribonucleotide formyltransferase (GARFTase), whereas AGF347 inhibited mito- chondrial C1 metabolism at serine hydroxymethyltransferase 2 (SHMT2), with additional effects on C1 metabolism in the cytosol (DNP biosynthesis at GARFTase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase, and at SHMT1). Both inhibitors depleted ATP; AGF347 depleted glycine and cytosolic C1 pools, with downstream effects on glutathione and levels of reactive oxygen species, and on mTOR signaling. AGF94 and AGF347 showed promising in vivo efficacies toward early and upstage tumor xeno- grafts. We posit that our PCFT-targeted agents offer an entirely new approach for treating cancer. In this R01 renewal, we explore the unique biology of the facilitative folate transporters and C1 metabolism, with a goal of further optimizing therapeutic applications of our novel agents. We propose in Aim 1 to characterize the cellular pharmacodynamics and molecular regulation of PCFT in relation to PCFT-targeted therapies, including transcriptional mechanisms and the role of protein-protein interactions in regulating PCFT. In Aim 2, we will characterize the cellular pharmacodynamics of mitochondrial C1 inhibitors including their transport and metabolism. An important focus of both Aims 1 and 2 will be on the role of the tumor microenvironment, including the impact of hypoxia and acid pH on anti-tumor drug biology and efficacy of these series. Our proposed studies are distinctive for their novelty and focus on clinical translation.
摘要

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Biology of the major facilitative folate transporters SLC19A1 and SLC46A1.
  • DOI:
    10.1016/b978-0-12-800223-0.00004-9
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Hou, Zhanjun;Matherly, Larry H.
  • 通讯作者:
    Matherly, Larry H.
Substrate-specific binding and conformational changes involving Ser313 and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking.
通过定点诱变和蛋白质交联测定涉及人还原叶酸载体的 Ser313 和跨膜结构域 8 的底物特异性结合和构象变化。
  • DOI:
    10.1042/bj20100181
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Hou,Zhanjun;Wu,Jianmei;Ye,Jun;Cherian,Christina;Matherly,LarryH
  • 通讯作者:
    Matherly,LarryH
Discovery of Tumor-Targeted 6-Methyl Substituted Pemetrexed and Related Antifolates with Selective Loss of RFC Transport.
  • DOI:
    10.1021/acsmedchemlett.3c00326
  • 发表时间:
    2023-12-14
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Kaku, Krishna;Ravindra, Manasa P.;Tong, Nian;Choudhary, Shruti;Li, Xinxin;Yu, Jianming;Karim, Mohammad;Brzezinski, Madelyn;O'Connor, Carrie;Hou, Zhanjun;Matherly, Larry H.;Gangjee, Aleem
  • 通讯作者:
    Gangjee, Aleem
Effects of 5' untranslated region diversity on the posttranscriptional regulation of the human reduced folate carrier.
5非翻译区多样性对人类还原叶酸载体转录后调节的影响。
  • DOI:
    10.1016/j.bbaexp.2006.12.006
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Payton,ScottG;Haska,ChristinaL;Flatley,RobinM;Ge,Yubin;Matherly,LarryH
  • 通讯作者:
    Matherly,LarryH
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhanjun Hou其他文献

Zhanjun Hou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhanjun Hou', 18)}}的其他基金

Biology of major folate transporters and STING signaling in cancer
主要叶酸转运蛋白的生物学和癌症中的 STING 信号传导
  • 批准号:
    10597540
  • 财政年份:
    2022
  • 资助金额:
    $ 29.26万
  • 项目类别:
Biology of major folate transporters and STING signaling in cancer
主要叶酸转运蛋白的生物学和癌症中的 STING 信号传导
  • 批准号:
    10435010
  • 财政年份:
    2022
  • 资助金额:
    $ 29.26万
  • 项目类别:
Molecular Regulation of Folate and Antifolate Transport
叶酸和抗叶酸转运的分子调节
  • 批准号:
    10438789
  • 财政年份:
    1993
  • 资助金额:
    $ 29.26万
  • 项目类别:
Molecular Regulation of Folate and Antifolate Transport
叶酸和抗叶酸转运的分子调节
  • 批准号:
    9025683
  • 财政年份:
    1993
  • 资助金额:
    $ 29.26万
  • 项目类别:
Molecular Regulation of Folate and Antifolate Transport
叶酸和抗叶酸转运的分子调节
  • 批准号:
    10163805
  • 财政年份:
    1993
  • 资助金额:
    $ 29.26万
  • 项目类别:

相似海外基金

CLINICAL TRIAL: ALIMTA AND GEMZAR IN ADVANCED PANCREATIC AND BILIARY TRACT CANCE
临床试验:ALIMTA 和 GEMZAR 治疗晚期胰腺癌和胆道癌
  • 批准号:
    7718420
  • 财政年份:
    2008
  • 资助金额:
    $ 29.26万
  • 项目类别:
ALIMTA AND GEMZAR IN ADVANCED PANCREATIC AND BILIARY TRACT CANCER
ALIMTA 和 GEMZAR 治疗晚期胰腺癌和胆道癌
  • 批准号:
    7605733
  • 财政年份:
    2007
  • 资助金额:
    $ 29.26万
  • 项目类别:
ALIMTA AND GEMZAR IN ADVANCED PANCREATIC AND BILIARY TRACT CANCER
ALIMTA 和 GEMZAR 治疗晚期胰腺癌和胆道癌
  • 批准号:
    7378319
  • 财政年份:
    2006
  • 资助金额:
    $ 29.26万
  • 项目类别:
ADVL0311, A PHASE I STUDY OF PEMETREXED (LY231514, ALIMTA) (NSC #698037, IND
ADVL0311,培美曲塞(LY231514,ALIMTA)的 I 期研究(NSC
  • 批准号:
    7374983
  • 财政年份:
    2005
  • 资助金额:
    $ 29.26万
  • 项目类别:
ALIMTA AND GEMZAR IN ADVANCED PANCREATIC AND BILIARY TRACT CANCER
ALIMTA 和 GEMZAR 治疗晚期胰腺癌和胆道癌
  • 批准号:
    7207168
  • 财政年份:
    2005
  • 资助金额:
    $ 29.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了